GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (STU:T3X) » Definitions » Additional Paid-In Capital

Telix Pharmaceuticals (STU:T3X) Additional Paid-In Capital : €360.9 Mil(As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telix Pharmaceuticals Additional Paid-In Capital?


Telix Pharmaceuticals's quarterly additional paid-in capital declined from Dec. 2023 (€273.9 Mil) to Jun. 2024 (€0.0 Mil) but then increased from Jun. 2024 (€0.0 Mil) to Dec. 2024 (€360.9 Mil).

Telix Pharmaceuticals's annual additional paid-in capital increased from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€273.9 Mil) and increased from Dec. 2023 (€273.9 Mil) to Dec. 2024 (€360.9 Mil).

Telix Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Telix Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Additional Paid-In Capital Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 273.91 360.94

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 273.91 - 360.94

Telix Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Telix Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (STU:T3X) » Definitions » Additional Paid-In Capital
Comparable Companies
ASX:MSB ASX:NEU ASX:OPT ASX:CU6 ASX:BOT ASX:PYC ASX:CUV ASX:IMM ASX:OCC ASX:IMU VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
TLX:USA TLPPF:USA T3X:Germany TLX:Australia
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Website
https://www.telixpharma.com
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Telix Pharmaceuticals Headlines

No Headlines